BIA-28-6156-111: Phase I, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BIA 28-6156 in Participants with Varying Degrees of Renal Impairment

pariceract (BIA 28-6156) - BIAL

Jun 15, 2026